Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May
Rhea-AI Summary
Editas Medicine (NASDAQ: EDIT), a gene editing company, has announced it will release its Q1 2025 financial results on May 12, 2025 through a press release and SEC filings. The company has discontinued its practice of hosting quarterly financial results conference calls.
Additionally, Editas management will participate in the Bank of America Global Healthcare Conference in Las Vegas on May 13, 2025 at 5:15 p.m. PT in a fireside chat format. The presentation will be accessible via webcast on the company's website, with a replay available for approximately 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – EDIT
In the trading session that priced this news, EDIT declined 13.64%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it plans to announce Q1 2025 financial results and business updates on May 12 via press release and SEC filings. As previously announced, the Company does not plan to host quarterly financial results conference calls moving forward.
Additionally, Editas Medicine management will participate in the following upcoming investor conference in May:
- Bank of America Global Healthcare Conference
Format: Fireside Chat
Date: Tuesday, May 13
Time: 5:15 p.m. PT
Location: Las Vegas, NV
To access the live webcast of Editas Medicine’s presentation, please visit the “Investors” section of the Company’s website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following the event.
About Editas Medicine
As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Media and Investor Contact: ir@editasmed.com